Vical in line for $10m milestone as CMV vaccine advances
This article was originally published in Scrip
Executive Summary
Vical is set to receive a $10 million milestone payment from Astellas based on progress with the design of a Phase III trial for the companies' therapeutic cytomegalovirus (CMV) vaccine for transplant recipients, TransVax.